Kerala physician Dr. Zubair Nabin lost 31 kilograms using the experimental obesity drug retatrutide. The report details the drug’s mechanism, benefits, side effects and the emerging challenges of sustained weight management.
Key Takeaways (मुख्य बिंदु)
- Dr. Nabin lost 31 kg with retatrutide, achieving a waist reduction from 44 to 36 inches.
- Retatrutide is a triple‑hormone agonist targeting GLP‑1, GIP and glucagon receptors.
- Rapid weight loss raised issues such as muscle loss, excess skin and social scrutiny.
Dr. Zubair Nabin, a 39‑year‑old physician from Kerala, grew up overweight and eventually weighed 120 kg. His love for extra portions of biryani and pastries was more emotional comfort than nutrition, trapping him in a cycle of overeating and failed diets.
What Is Retatrutide?
Retatrutide is an experimental GLP‑1‑based drug that simultaneously activates three hormone receptors—GLP‑1, GIP and glucagon. By mimicking incretin hormones, it boosts insulin secretion, suppresses glucagon‑driven hepatic glucose production and slows gastric emptying, thereby curbing appetite. The compound is still in clinical trials and has not received regulatory approval for general use.
Weight‑Loss Results and Comparisons
Two years ago Dr. Nabin enrolled in the trial after shedding only 10 kg through diet and exercise. On the drug, he dropped from 120 kg to 89 kg—a 31 kg loss and a waist reduction from 44 inches to 36 inches. Phase‑3 data show that at 80 weeks, the 4 mg dose yielded a 19 % weight loss, 9 mg achieved 25.9 % and the 12 mg dose produced 28.3 % loss—outperforming semaglutide (~15 % over 68 weeks) and tirzepatide (~20‑21 % over 72 weeks).
Body Image and Social Consequences
While the scale numbers improved confidence, Dr. Nabin reported muscle thinning and a feeling of reduced strength. Dr. Jothydev Kesavadev, who oversaw the trial in Kochi, noted that participants often faced unsolicited comments—“you look too thin,” “are you eating enough,” or “you look older.” A small study of 167 participants presented at the American Diabetes Association linked such social pressure to discontinuation of GLP‑1 therapies, underscoring the need to focus on clinical metrics rather than appearance.
Future Outlook and Clinical Guidance
To counter muscle loss, Dr. Nabin has started resistance training. Other patients now grapple with excess abdominal skin, which may require surgical correction. Experts speculate that potent agents like retatrutide could eventually diminish the role of bariatric surgery, but long‑term safety, metabolic effects and mental‑health monitoring must remain central to treatment protocols.
